OPN-IN-1

Name: OPN-IN-1
Brand: MedChemExpress
SKU: HY-146064
Rating: 5.0 (9 reviews)

Cat. No.: HY-146064 Purity: 99.98%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

OPN-IN-1 is an osteopontin (OPN) expression inhibitor. OPN-IN-1 has potential anti-breast cancer cell metastasis activity and can be used in the study of cancer.

For research use only. We do not sell to patients.

CAS No. : 2257492-95-6

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

9 Publications Citing Use of MCE OPN-IN-1

Cell Migration/Invasion Assay

Cell Proliferation/Viability Assay

In Vivo Efficacy Study

: OPN-IN-1 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Dec 26.; OPNi-1 (50 μM, 24 h) decreased the protein expression of YKL40, EFEMP-1, and CD44 in BNI_2-4 cells after culture with hypoxic conditioned medium derived from THP-1 and U937.

: OPN-IN-1 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Dec 26.; OPNi-1 (50 μM, 48 h) decreased cell migration in BNI_2-4 cells after culture with hypoxic conditioned medium derived from THP-1 (L) and U937.

: OPN-IN-1 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Dec 26.; OPNi-1 (50 μM, 48 h) inhibited cell growth of BNI_2-4 cells following culture with hypoxic conditioned medium from THP-1 (L) and U937.

: OPN-IN-1 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Dec 26.; OPNi-1 (0.5 mg/kg, intraperitoneal injections, 5 consecutive days followed by a 2-day drug holiday, and repeat the cycle) inhibited tumor growth compared with the control treatment in an orthotopic mouse model of GBM using GL261 cells in C57BL/6J mice.

: OPN-IN-1 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Dec 26.; OPNi-1 (0.5 mg/kg, intraperitoneal injections, 5 consecutive days followed by a 2-day drug holiday, and repeat the cycle) reduced PD-L1 expression in an orthotopic mouse model of GBM using GL261 cells in C57BL/6J mice.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

OPN-IN-1 is an osteopontin (OPN) expression inhibitor. OPN-IN-1 has potential anti-breast cancer cell metastasis activity and can be used in the study of cancer^[1].

In Vitro

OPN-IN-1 (Compound 11) (50 μM; 24 h) can inhibit the expression of osteopontin (OPN) in MDA-MB-435 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	MDA-MB-435
Concentration:	50 μM
Incubation Time:	24 h
Result:	Decreased OPN expression by ~ 0.3 fold.

Molecular Weight

455.55

Formula

C₂₅H₃₃N₃O₅

CAS No.

2257492-95-6

Appearance

Solid

Color

White to yellow

SMILES

[H][C@@]12CC[C@]3(OO[C@]14[C@@H](O3)OC([C@@H]([C@@]4(CC[C@H]2C)[H])C)OCC5=CN(N=N5)CC6=CC=CC=C6)C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (219.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1951 mL	10.9757 mL	21.9515 mL
5 mM	0.4390 mL	2.1951 mL	4.3903 mL
10 mM	0.2195 mL	1.0976 mL	2.1951 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.49 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.49 mM); Suspended solution

This protocol yields a suspended solution of ≥ 2.5 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.49 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.98%

Select Batch:

Data Sheet (277 KB) SDS (251 KB)

COA (256 KB) HNMR (273 KB) LCMS (85 KB)

Handling Instructions (2659 KB)

References

[1]. Pasupuleti BG, et al. 1,2,3-Triazole tethered 1,2,4-trioxanes: Studies on their synthesis and effect on osteopontin expression in MDA-MB-435 breast cancer cells. Eur J Med Chem. 2020 Jan 15;186:111908. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1951 mL	10.9757 mL	21.9515 mL	54.8787 mL
	5 mM	0.4390 mL	2.1951 mL	4.3903 mL	10.9757 mL
	10 mM	0.2195 mL	1.0976 mL	2.1951 mL	5.4879 mL
	15 mM	0.1463 mL	0.7317 mL	1.4634 mL	3.6586 mL
	20 mM	0.1098 mL	0.5488 mL	1.0976 mL	2.7439 mL
	25 mM	0.0878 mL	0.4390 mL	0.8781 mL	2.1951 mL
	30 mM	0.0732 mL	0.3659 mL	0.7317 mL	1.8293 mL
	40 mM	0.0549 mL	0.2744 mL	0.5488 mL	1.3720 mL
	50 mM	0.0439 mL	0.2195 mL	0.4390 mL	1.0976 mL
	60 mM	0.0366 mL	0.1829 mL	0.3659 mL	0.9146 mL
	80 mM	0.0274 mL	0.1372 mL	0.2744 mL	0.6860 mL
	100 mM	0.0220 mL	0.1098 mL	0.2195 mL	0.5488 mL

OPN-IN-1 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

OPN-IN-12257492-95-6OsteopontinSecreted Phosphoprotein 1MDA-MB-435breast cancercancer metastasisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

OPN-IN-1

Customer Review

OPN-IN-1 Related Antibodies

9 Publications Citing Use of MCE OPN-IN-1

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

OPN-IN-1 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

OPN-IN-1 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report